Skip to main content
. 2016 Oct 14;6:35173. doi: 10.1038/srep35173

Figure 6. The antibody production of aAVC systems requires Bcl6 in Tfh cells.

Figure 6

(a) Serum OVA-specific antibody isotype of WT and Bcl6f/f-CD4-Cre mice immunized with aAVC-OVA. OVA specific IgG1 and IgG2b levels in serum were examined 2 and 4 weeks later. (Mean ± SEM, n = 5–7) **P < 0.01, ***P < 0.001. (b,c) 1 × 105 OT-II cells (CD90.2+) or Bcl6f/f-CD4-Cre OT-II cells (CD90.2+) were transferred into B6.PL mice (CD90.1+). On the following day, the mice were immunized with aAVC-OVA. The total cell number of OT-II (b) and the frequency of Tfh type OT-II cells (c) in spleen of vaccinated mice were assessed 5 days after immunization using CD4-FITC, CD90.2-PE, CXCR5-APC, and PD-VB. Data are representative of four mice. (d,e) 1 × 105 CD45.1+ OT-II cells were transferred into WT or Bcl6f/f-CD4-Cre mice and immunized with aAVC-OVA on the following day. OT-II cells in spleen were analyzed for the expression of CD44 and CD62 (d) and Tfh phenotype (e) 5 days after immunization. Data are representative of four mice. (f) 1 × 106 OT-II cells were transferred into WT or Bcl6f/f-CD4-Cre mice. On the following day, the mice were immunized with aAVC-OVA, and OVA-specific serum IgG2b levels were examined 2 weeks later. (n = 10), *P < 0.05.